MEPSGEN
Company Details
Status: Private
Employees: 11-50
Location:
seoul, korea, republic of
Type:
sample
sample
sample
sample
Technology:
sample
sample
sample
About: MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development.
The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments.
MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com
[ Industry ]
Drug Discovery
Drug Delivery
Biotechnology
[ Technology ]
MEPS-X series - 3D Microphysiological System platforms
MST-X series - Microvortex System, Nanoparticle manufacturing platform
MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
MEPSGEN | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.